273 related articles for article (PubMed ID: 21513849)
1. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Karlsson IM; Ge Y; Giske CG
Diagn Microbiol Infect Dis; 2011 May; 70(1):137-41. PubMed ID: 21513849
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kahlmeter G; Giske CG
APMIS; 2011 Dec; 119(12):853-63. PubMed ID: 22085361
[TBL] [Abstract][Full Text] [Related]
3. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Ge Y
J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
[TBL] [Abstract][Full Text] [Related]
4. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.
Ensor VM; Shahid M; Evans JT; Hawkey PM
J Antimicrob Chemother; 2006 Dec; 58(6):1260-3. PubMed ID: 17071956
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
7. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
[TBL] [Abstract][Full Text] [Related]
8. Distribution of CTX-M group I and group III β-lactamases produced by Escherichia coli and klebsiella pneumoniae in Lahore, Pakistan.
Abrar S; Vajeeha A; Ul-Ain N; Riaz S
Microb Pathog; 2017 Feb; 103():8-12. PubMed ID: 27956216
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of extended-spectrum beta-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia.
Severin JA; Mertaniasih NM; Kuntaman K; Lestari ES; Purwanta M; Lemmens-Den Toom N; Duerink DO; Hadi U; van Belkum A; Verbrugh HA; Goessens WH;
J Antimicrob Chemother; 2010 Mar; 65(3):465-9. PubMed ID: 20053690
[TBL] [Abstract][Full Text] [Related]
12. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
13. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China.
Yu Y; Ji S; Chen Y; Zhou W; Wei Z; Li L; Ma Y
J Infect; 2007 Jan; 54(1):53-7. PubMed ID: 16533535
[TBL] [Abstract][Full Text] [Related]
14. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
[TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
16. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
17. Molecular and phenotypic characterization of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases with focus on CTX-M in a low-endemic area in Sweden.
Onnberg A; Mölling P; Zimmermann J; Söderquist B
APMIS; 2011 Apr; 119(4-5):287-95. PubMed ID: 21492229
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
[TBL] [Abstract][Full Text] [Related]
19. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.
Martinez P; Garzón D; Mattar S
Braz J Infect Dis; 2012; 16(5):420-5. PubMed ID: 22964287
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
